查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1890922

腦腫瘤治療市場：依治療方法、腫瘤類型、藥物分類、年齡層、性別、最終用戶、通路和地區分類

Brain Tumor Treatment Market, By Treatment Modality, By Tumor Type, By Drug Class, By Age Group, By Gender, By End User, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，腦腫瘤治療市場價值將達到 23.4 億美元，到 2032 年將達到 45.3 億美元，2025 年至 2032 年的複合年成長率為 9.9%。

報告覆蓋範圍 報告詳情
基準年： 2024 2025年市場規模： 23.4億美元
歷史數據時期： 2020年至2024年 預測期： 2025年至2032年
預測期（2025-2032年）複合年成長率： 9.90% 預計2032年價值： 45.3億美元

全球腦腫瘤治療市場是更廣泛的腫瘤治療領域中的重要細分市場，它致力於解決影響中樞神經系統的最複雜、最具挑戰性的疾病之一。

腦腫瘤的特徵是腦組織內或周圍的細胞異常增生，包括起源於腦部的原發性腫瘤和從其他部位轉移而來的繼發次發性腫瘤。治療方案採用多管齊下的方法，結合手術、放射線治療、化療、標靶治療和新興的免疫療法，每種療法都根據特定的腫瘤類型、原發部位和患者病情量身定做。

該市場的重要性不僅限於傳統治療方法，還涵蓋立體定位放射放射線手術、腫瘤電場治療以及基於分子譜分析的個人化醫療等先進技術。全球腦腫瘤發生率的上升、人口老化以及診斷技術的進步，都在推動對有效治療方案的需求。

人工智慧融入治療方案製定、血腦障壁滲透性藥物的研發以及微創手術技術的進步正在重塑治療通訊協定。世界各地的醫療系統都在加大對神經腫瘤專科中心和尖端設備的投入，而製藥公司也在加速研發，以滿足這一充滿挑戰的治療領域尚未滿足的醫療需求。

市場動態

全球腦腫瘤治療市場受多種強勁因素驅動，持續塑造其成長軌跡，同時也面臨一些顯著的限制因素，為相關人員帶來了巨大的機會。主要市場促進因素包括：全球各年齡層腦腫瘤發生率的不斷上升；老年人口的成長（老年人尤其容易患各種類型的腫瘤）；以及患者和醫療保健提供者對早期診斷和治療方案的認知不斷提高。

高解析度磁振造影（MRI）、正子斷層掃描（PET）和分子診斷等先進診斷技術能夠更早、更準確地發現腫瘤，從而推動了治療需求。標靶治療、免疫療法和基於基因譜的個人化醫療等新型治療方法的快速發展，正在拓展治療選擇，改善患者預後。然而，腦腫瘤治療費用極高仍是一個主要阻礙因素。治療通常需要漫長而複雜的治療方案、專用醫療設備以及長期住院，這給患者和醫療系統都帶來了沉重的經濟負擔。

血腦障壁是一項重大的生物學挑戰，它限制了藥物輸送的有效性，並縮小了治療選擇範圍。此外，腦腫瘤複雜的解剖位置使得手術介入本身就風險極高，有時甚至根本無法進行。新治療方法的嚴格監管核准流程以及罕見腦腫瘤患者群體相對較小的特點，都給製藥公司帶來了額外的挑戰。

本次調查的主要特點

  • 本報告對全球腦腫瘤治療市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和復合年成長率百分比。
  • 該報告還重點介紹了各個細分市場的潛在商機，並概述了該市場具有吸引力的投資提案矩陣。
  • 該研究還提供了有關市場促進因素、阻礙因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
  • 該研究根據以下參數對全球腦腫瘤治療市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
  • 本研究主要企業包括：羅氏製藥有限公司、諾華製藥有限公司、默克公司、輝瑞公司、拜耳公司、衛材株式會社、百時美施貴寶公司、安進公司、葛蘭素史克公司、強生公司、阿斯特捷利康公司、y-Mabs Therapeutics公司、Emcure Pharmaceuticals 有限公司、Nextuticalceticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Nextuticals LLC、Next LLCs Pharmaceuticals）公司。
  • 本報告的研究結果將使負責人和經營團隊能夠就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
  • 這份全球腦腫瘤治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過各種用於分析全球腦腫瘤治療市場的策略矩陣輕鬆做出決策。

目錄

第1章 研究目標與前提條件

  • 調查目的
  • 先決條件
  • 簡稱

第2章 市場範圍

  • 報告概述
    • 市場定義和範圍
  • 執行摘要

第3章 市場動態、監管與趨勢分析

  • 市場動態
  • 促進要素
  • 抑制因素
  • 機會
  • 影響分析
  • 重大進展
  • 法規環境
  • 產品上市及核准
  • PEST分析
  • 波特分析
  • 併購趨勢
  • 產業趨勢

4. 2020-2032年全球腦腫瘤治療市場（依治療方法）

  • 化療（例如，烷化劑、細胞毒性藥物）
  • 放射線治療（例如體外放射治療、立體定位放射線手術）
  • 標靶治療（例如，分子標靶小分子化合物）
  • 免疫療法（例如，查核點抑制劑、CAR-T療法）
  • 其他治療方法（例如，腫瘤治療電場療法、基因療法、聯合治療）

5. 2020-2032年全球腦腫瘤治療市場（依腫瘤類型分類）

  • 原發性腦瘤（例如，膠質母細胞瘤、星狀細胞瘤）
  • 轉移性/次發性腦腫瘤
  • 腦膜瘤
  • 腦下垂體瘤
  • 其他腫瘤類型（例如少突膠質細胞瘤、室管膜瘤）

6. 2020-2032年全球腦腫瘤治療市場（依藥物分類）

  • 烷化劑
  • 抗代謝物
  • 單株抗體
  • 小分子抑制劑
  • 其他藥物類別（例如，蛋白酶體抑制劑、表觀遺傳調節劑）

7. 2020-2032年全球腦腫瘤治療市場（依年齡層分類）

  • 兒童
  • 成人
  • 老年人

8. 2020-2032年全球腦腫瘤治療市場（依性別分類）

  • 男性
  • 女士

9. 2020-2032年全球腦腫瘤治療市場（依最終使用者分類）

  • 醫院及綜合癌症中心
  • 門診手術中心/門診護理中心
  • 專科診所（神經腫瘤科診所）
  • 居家醫療/遠端醫療環境（如適用）

第10章 全球腦腫瘤治療市場（依通路分類），2020-2032年

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第11章 2020-2032年全球腦腫瘤治療市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲國家
  • 歐洲
    • 德國
    • 英國
    • 西班牙
    • 法國
    • 義大利
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 亞太其他地區
  • 中東
    • 海灣合作理事會國家
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 北非
    • 中非

第12章 競爭格局

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals plc
  • Sun Pharmaceutical Industries Ltd.
  • Johnson and Johnson
  • Viatris Inc.
  • Hikma Pharmaceuticals plc
  • Aurobindo Pharma Ltd.
  • Endo International plc
  • Mylana€¯NV（現為 Viatris）
  • 默克集團
  • BristolMyers Squibb Company
  • Grunenthal GmbH
  • Sanofi SA
  • AbbVie Inc.

第13章 分析師建議

  • 機會
  • 分析師觀點
  • Coherent Opportunity Map

第14章 參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI8946

Brain Tumor Treatment Market is estimated to be valued at USD 2.34 Bn in 2025 and is expected to reach USD 4.53 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 2.34 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 9.90% 2032 Value Projection: USD 4.53 Bn

The global brain tumor treatment market represents a critical segment within the broader oncology therapeutics landscape, addressing one of the most complex and challenging medical conditions affecting the central nervous system.

Brain tumors, characterized by abnormal cell growth within or around the brain tissue, encompass both primary tumors originating in the brain and secondary metastatic tumors spreading from other body parts. The treatment paradigm involves a multidisciplinary approach combining surgical interventions, radiation therapy, chemotherapy, targeted therapy, and emerging immunotherapy options, each tailored to specific tumor types, locations, and patient conditions.

The market's significance extends beyond traditional therapeutic modalities, incorporating advanced technologies such as stereotactic radiosurgery, tumor-treating fields, and personalized medicine approaches based on molecular profiling. Rising incidence rates of brain tumors globally, coupled with an aging population and improved diagnostic capabilities, have intensified the demand for effective treatment solutions.

The integration of artificial intelligence in treatment planning, development of blood-brain barrier penetrating drugs, and advancement in minimally invasive surgical techniques are reshaping treatment protocols. Healthcare systems worldwide are increasingly investing in specialized neuro-oncology centers and cutting-edge equipment, while pharmaceutical companies are accelerating research and development efforts to address unmet medical needs in this challenging therapeutic area.

Market Dynamics

The global brain tumor treatment market is propelled by several compelling drivers that continue to shape its growth trajectory, while simultaneously facing notable restraints and presenting significant opportunities for stakeholders. The primary market drivers include the escalating global incidence of brain tumors across all age groups, with particular emphasis on the growing geriatric population that exhibits higher susceptibility to various tumor types, alongside increasing awareness about early diagnosis and treatment options among patients and healthcare providers.

Advanced diagnostic technologies such as high-resolution MRI, PET scans, and molecular diagnostics are enabling earlier and more precise tumor detection, subsequently driving treatment demand. The rapid development of novel therapeutic approaches, including targeted therapies, immunotherapies, and personalized medicine based on genetic profiling, is expanding treatment possibilities and improving patient outcomes. However, the market faces substantial restraints including the extremely high costs associated with brain tumor treatments, which often require prolonged multi-modal therapy approaches, specialized equipment, and extended hospitalization periods that create financial barriers for patients and healthcare systems.

The blood-brain barrier presents a significant biological challenge, limiting drug delivery effectiveness and reducing therapeutic options, while the complex anatomical location of brain tumors makes surgical interventions inherently risky and sometimes impossible. Stringent regulatory approval processes for new therapies, coupled with the relatively small patient population for rare brain tumor types, create additional challenges for pharmaceutical companies.

Key Features of the Study

  • This report provides in-depth analysis of the global brain tumor treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global brain tumor treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered in this study include F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co., Inc., Pfizer Inc., Bayer AG, Eisai Co., Ltd., Bristol-Myers Squibb Company, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca PLC, y-Mabs Therapeutics Inc., Emcure Pharmaceuticals Ltd., NextSource Pharmaceuticals LLC, and Daiichi Sankyo Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global brain tumor treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brain tumor treatment market

Market Segmentation

  • Treatment Modality Insights (Revenue, USD Bn, 2020 - 2032)
    • Chemotherapy (e.g., alkylating agents, cytotoxic drugs)
    • Radiation Therapy (e.g., external beam radiation, stereotactic radiosurgery)
    • Targeted Therapy (e.g., molecularly targeted small molecules)
    • Immunotherapy (e.g., checkpoint inhibitors, CAR T therapies)
    • Other Therapies (e.g., tumor treating fields, gene therapy, combination modalities)
  • Tumor Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Primary Brain Tumors (e.g., glioblastoma, astrocytoma)
    • Metastatic/Secondary Brain Tumors
    • Meningioma
    • Pituitary Tumors
    • Other Tumor Types (e.g., oligodendroglioma, ependymoma)
  • Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
    • Alkylating Agents
    • Antimetabolites
    • Monoclonal Antibodies
    • Small Molecule Inhibitors
    • Other Drug Classes (e.g., proteasome inhibitors, epigenetic modulators)
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Pediatric
    • Adult
    • Geriatric
  • Gender Insights (Revenue, USD Bn, 2020 - 2032)
    • Male
    • Female
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals and Integrated Cancer Centers
    • Ambulatory Surgical/Outpatient Centers
    • Specialty Clinics (neuro oncology clinics)
    • Home Care/Remote Care Settings (where applicable)
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mallinckrodt Pharmaceuticals plc
    • Sun Pharmaceutical Industries Ltd.
    • Johnson and Johnson
    • Viatris Inc.
    • Hikma Pharmaceuticals plc
    • Aurobindo Pharma Ltd.
    • Endo International plc
    • Mylan N.V. (now Viatris)
    • Merck KGaA
    • Bristol Myers Squibb Company
    • Grunenthal GmbH
    • Sanofi S.A.
    • AbbVie Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Brain Tumor Treatment Market, By Treatment Modality
    • Global Brain Tumor Treatment Market, By Tumor Type
    • Global Brain Tumor Treatment Market, By Drug Class
    • Global Brain Tumor Treatment Market, By Age Group
    • Global Brain Tumor Treatment Market, By Gender
    • Global Brain Tumor Treatment Market, By End User
    • Global Brain Tumor Treatment Market, By Distribution Channel
    • Global Brain Tumor Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Brain Tumor Treatment Market, By Treatment Modality, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Chemotherapy (e.g., alkylating agents, cytotoxic drugs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Radiation Therapy (e.g., external beam radiation, stereotactic radiosurgery)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Targeted Therapy (e.g., molecularly targeted small molecules)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Immunotherapy (e.g., checkpoint inhibitors, CART therapies)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Therapies (e.g., tumortreating fields, gene therapy, combination modalities)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Brain Tumor Treatment Market, By Tumor Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Primary Brain Tumors (e.g., glioblastoma, astrocytoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Metastatic/Secondary Brain Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Meningioma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pituitary Tumors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Tumor Types (e.g., oligodendroglioma, ependymoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Brain Tumor Treatment Market, By Drug Class, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Alkylating Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • SmallMolecule Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Drug Classes (e.g., proteasome inhibitors, epigenetic modulators)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Brain Tumor Treatment Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Brain Tumor Treatment Market, By Gender, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Male
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Female
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Brain Tumor Treatment Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals and Integrated Cancer Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical/Outpatient Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics (neurooncology clinics)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Care/Remote Care Settings (where applicable)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Brain Tumor Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Brain Tumor Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Tumor Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mallinckrodt Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson and Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hikma Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aurobindo Pharma Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Endo International plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mylana€¯N.V. (now Viatris)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mercka€¯KGaA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BristolMyers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Grunenthal GmbH
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us